Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.79 and traded as high as $5.24. Galectin Therapeutics shares last traded at $5.05, with a volume of 257,960 shares changing hands.
Wall Street Analysts Forecast Growth
GALT has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price target on shares of Galectin Therapeutics in a report on Thursday, August 14th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Galectin Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $6.00.
View Our Latest Research Report on GALT
Galectin Therapeutics Stock Performance
The company's 50-day moving average price is $4.46 and its 200 day moving average price is $2.79. The stock has a market cap of $323.50 million, a PE ratio of -7.89 and a beta of 0.85.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. On average, sell-side analysts anticipate that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.
Insider Buying and Selling at Galectin Therapeutics
In related news, CFO Jack W. Callicutt sold 8,706 shares of the firm's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $6.44, for a total value of $56,066.64. Following the transaction, the chief financial officer directly owned 7,614 shares of the company's stock, valued at approximately $49,034.16. This trade represents a 53.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Joel Lewis sold 14,000 shares of Galectin Therapeutics stock in a transaction on Friday, September 12th. The shares were sold at an average price of $6.36, for a total value of $89,040.00. Following the transaction, the chief executive officer owned 832,592 shares in the company, valued at $5,295,285.12. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 50.10% of the company's stock.
Institutional Investors Weigh In On Galectin Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in shares of Galectin Therapeutics in the second quarter worth $1,580,000. Y Intercept Hong Kong Ltd bought a new position in Galectin Therapeutics during the first quarter valued at approximately $287,000. Vivaldi Capital Management LP boosted its stake in Galectin Therapeutics by 210.0% during the second quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company's stock valued at $364,000 after buying an additional 116,815 shares during the last quarter. Wealthspire Advisors LLC grew its holdings in Galectin Therapeutics by 20.4% during the 2nd quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company's stock valued at $1,012,000 after buying an additional 81,144 shares in the last quarter. Finally, Truist Financial Corp bought a new stake in Galectin Therapeutics in the 2nd quarter worth approximately $143,000. 11.68% of the stock is owned by institutional investors.
Galectin Therapeutics Company Profile
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
